

Anticonvulsant Screening Program (ASP) is a long-standing government sponsored effort established to encourage and facilitate the discovery, optimization and development of new therapeutic agents for the treatment of seizure related disorders. One of the ASP's major goals is to establish international collaborative partnerships among governments, academia, and industry that act to stimulate the search and development of better treatments and an eventual cure for the epilepsies. Recently, through a broader HHS funded effort, the ASP has expanded its screening capabilities. We are now accepting compounds intended to act as counter-measures against potential chemical threats stemming from either intentional or accidental exposure to various nerve agents. For this purpose, the ASP now employs a series of models that mimic the effects of CNS exposure to nerve agents (actual nerve agents are not used in evaluations). To participate or for more information please contact a member of our program staff listed in our website (http://www.ninds.nih.gov/asp).

